No Data
No Data
No Data
No Data
No Data
Express News | Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of Onct-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer
Moomoo 24/7Apr 18 09:00 ET
Oppenheimer Reaffirms Their Hold Rating on Oncternal Therapeutics (ONCT)
TipRanksApr 17 07:45 ET
Oncternal Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Oncternal Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow JonesApr 15 06:20 ET
Oncternal Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/15/2024 197.87% HC Wainwright & Co. $30 → $28 Maintains Buy 01/29/2024 219.15% HC Wainwright & Co. $2 →
BenzingaApr 15 06:08 ET
Express News | Oncternal Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $28 From $30
Moomoo 24/7Apr 15 06:05 ET
AIVITA Biomedical CEO Dr. Hans Keirstead and CMO Dr. Robert Dillman to Speak and Participate in Keynote Panel at Festival of Biologics USA
IRVINE, Calif., April 11, 2024 /PRNewswire/ -- AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, today announced that chief executive officer Hans Keirstea
PR NewswireApr 11 13:10 ET
Den the Dragon : how deep is the water
Darkwalker : Good luck.
Jesus is lordOP Den the Dragon: I won't lie I have never had good experiences with this stock I am investing only tiny bitty position so that I can avg down conveniently without crying and if it goes up profit is profit
Jesus is lordOP Darkwalker: thanks
No Data
No Data